N

Nicholas J. Laping

University of Southern California

Publishes on TGF-β signaling in diseases, Urinary Bladder and Prostate Research, S100 Proteins and Annexins. 101 papers and 8k citations.

101Publications

8kTotal Citations

TGF-β signaling in diseases Urinary Bladder and Prostate Research S100 Proteins and Annexins Estrogen and related hormone effects Clusterin in disease pathology

Is this you? Claim your profile.

Add your photo, update your bio, and get notified when your ranking changes.

Top publicationsby citations

SB-431542 Is a Potent and Specific Inhibitor of Transforming Growth Factor-β Superfamily Type I Activin Receptor-Like Kinase (ALK) Receptors ALK4, ALK5, and ALK7

Gareth J. Inman, Francisco José Nicolás, James F. Callahan et al.|Molecular Pharmacology|2002

Cited by 1.7k

Inhibition of Transforming Growth Factor (TGF)-β1–Induced Extracellular Matrix with a Novel Inhibitor of the TGF-β Type I Receptor Kinase Activity: SB-431542

Nicholas J. Laping, Eugene T. Grygielko, Anil Mathur et al.|Molecular Pharmacology|2002

Cited by 650

GFAP mRNA increases with age in rat and human brain

Nancy R. Nichols, Jonathan Day, Nicholas J. Laping et al.|Neurobiology of Aging|1993

Cited by 419

SB-505124 Is a Selective Inhibitor of Transforming Growth Factor-β Type I Receptors ALK4, ALK5, and ALK7

Stacey DaCosta Byfield, Christopher Major, Nicholas J. Laping et al.|Molecular Pharmacology|2004

Cited by 416

N-((1 S)-1-{[4-((2 S)-2-{[(2,4-Dichlorophenyl)sulfonyl]amino}-3-hydroxypropanoyl)-1-piperazinyl]carbonyl}-3-methylbutyl)-1-benzothiophene-2-carboxamide (GSK1016790A), a Novel and Potent Transient Receptor Potential Vanilloid 4 Channel Agonist Induces Urinary Bladder Contraction and Hyperactivity: Part I

Kevin S. Thorneloe, Anthony C. Sulpizio, Zuojun Lin et al.|Journal of Pharmacology and Experimental Therapeutics|2008

Cited by 403